Bronchodilator responsiveness and onset of effect with budesonide/ formoterol pMDI in COPD

Respiratory Medicine

Volumn 105, Issue 8, 2011, Pages 1176-1188

  Celli, Bartolome R ^a   Tashkin, Donald P ^b   Rennard, Stephen I ^c   McElhattan, Jennifer ^d   Martin, Ubaldo J ^d  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Bronchodilation; COPD; Lung volume; Onset of effect; Reversibility; Treatment

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL;

ADULT; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; POWDER INHALER; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; VITAL CAPACITY;

EID: 79959188212     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2011.02.020     Document Type: Article

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, updated 2010. Available from: http://www.goldcopd.com [accessed April 15, 2011].
2. Celli BR, MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
3. Halpin D. NICE guidance for COPD. Thorax 2004;59(Suppl. 1):1-232.
4. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123:1441-9. (Pubitemid 36549761)
5. Mahler DA, Donohue JF, Barbee RA. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65. (Pubitemid 29193661)
6. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.
7. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
8. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9. (Pubitemid 37540641)
9. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
10. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. (Pubitemid 36150304)
11. Jenkins CR, Jones PW, Calverley PMA, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59.
12. Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004;17:121-5. (Pubitemid 38496186)
13. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007;12:732-9. (Pubitemid 47414887)
14. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68:1975-2000.
15. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549-65.
16. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
17. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
18. Goedhart DM, Zanen P, Kerstjens HAM, Lammers JJ. Discriminating asthma and COPD based on bronchodilator data: an improvement of the methods. Physiol Meas 2005;26:1115-23. (Pubitemid 41744568)
19. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretive strategies for lung function tests. Eur Respir J 2005;26:948-68. (Pubitemid 41632054)
20. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-68.
21. Bleecker ER, Emmett A, Crater G, Knobil K, Kalberg C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008;21:682-8.
22. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002;121:1042-50. (Pubitemid 34280421)
23. Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64. for the ISOLDE Study Investigators.
24. 2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
25. Taylor DR, Hancox RJ. Interactions between corticosteroids and beta agonists. Thorax 2000;55:595-602.
26. 1 reversibility. Curr Med Res Opin 2004;20:581-6.
27. Ben Saad H, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther 2008;21:767-73.
28. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000;16:269-75. (Pubitemid 30627482)
29. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-min-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395-9. (Pubitemid 32506605)
30. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinhalation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:15-65.
31. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-7. (Pubitemid 40365414)
32. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8.